Cel-Sci: Developing A First-Line Therapy For Cancer Using The Bodys Own Anti-Tumor Immune Response

CEL-SCI: Developing a First-Line Therapy for Cancer Using the Body’s Own Anti-Tumor Immune Response

RedChip Companies

Geert Kersten: Creating the First Cancer Drug to be Administered before Surgery

Palisades Gold Radio

CEL-SCI Corp (NYSE:CVM) CEO on Successful Immunotherapy Cancer Treatment Trials

CEL-SCI Corporation - Update on Multikine

JV Public Relations NY

CEL-SCI Gov Approval in Bosnia and Herzegovina for Phase III Trial of Multikine

CorporateProfile

CEL-SCI Receives Approval to Expand Its Immunotherapy Phase III Cancer Trial into the UK

CorporateProfile

CEL-SCI Government Approval in Serbia for Phase III Clinical Trial of Multikine

CorporateProfile

Breakthrough Cancer Treatments: How Immunotherapy is Saving Lives | MediGence

CEL-SCI Talks Phase 3 Head and Neck Cancer Study, Immunotherapy for COVID-19 in Corporate Update

Planet MicroCap

CEL-SCI Conducts Mtg of North American Clinical Centers for Phase III Cancer Trial w/ Multikine

CorporateProfile

CEL-SCI Advances Regulatory Approval for Multikine

CorporateProfile

CEL-SCI Clinical Investigator Mtg. for Centers Participating in Phase III Cancer Trial w/ Multikine

CorporateProfile

CEL-SCI Enrolls 20 Patients in August in Its Phase III Immunotherapy Head and Neck Cancer Trial

CorporateProfile

CEL-SCI Expands Its Phase III Head and Neck Cancer Trial into Sri Lanka

CorporateProfile

CEL-SCI hopeful new data will show 10% improvement in cancer patients

Proactive Investors

Henry Ford Health System to Enroll and Treat Patients in CEL-SCI's Phase III Cancer Clinical Trial

CorporateProfile

First U.S. Clinical Site for CVM's Global Phase III Immunotherapy Head & Neck Cancer Trial Expansion

CorporateProfile

CEL-SCI Cancer Immunotherapy

Brandon Schwartz

CEL-SCI Announces IDMC Conclusions From Interim Review of Phase III Head and Neck Cancer Trial Data

CorporateProfile